AARTI HEALTHCARE, is an API division of AARTI INDUSTRIES LTD, Flagship Company of USD 189 million strong "Aarti Group", with export turnover of USD 67 million to more than 65 countries all over the world. Aarti Group has more than 29 years of rich experience in manufacturing of chemicals, Intermediates, Bulk Drugs, API's, and manufactures more than 200 products at 5 different locations.

Two major companies in the group, Aarti Industries Ltd. and Aarti Drugs Ltd. are listed on Mumbai Stock Exchange. Aarti Healthcare is focused on Niche Molecules mainly in therapeutic categories of Cardiovascular, CNS, Bronchodilator & Anti-Cancer molecules. They are all High Value and Low Volume products, where patent has just expired or about to expire.

Aarti Healthcare offers innovative Non-Infringing Processes, backed up by patent search cell and also offers Technical Packages, DMF in CTD Format, complete study of impurity profile, stability study and polymorphs studies.

Besides matching specifications per International Pharmacopoeia, BP/USP/EP, Aarti Healthcare offers tailor-made products matching in-house specification of clients both chemical & physical properties including Bulk Density and Particle Size distribution.

Aarti Healthcare has more than 6 Jet-Mill in house and has the required skill and expertise for micronisation and can offer particle size of as low as 2.5 micron. The present API Facility at Dombivali is as per WHO c-GMP norms and ICH Guidelines.

Aarti Healthcare has commissioned New Facility at Vapi in India in Sept. 2004 dedicated to manufacturing of Intermediates of APIs, thus feeding to existing Facility and new upcoming Facility. This Facility is coming up at Tarapur in India, is US-FDA compliant, and expected to commission in 1st quarter of 2005 and should receive FDA approval by early 2006.This Facility will have 3 separate blocks for Non Steroidal APIs, Steroids, Anti-Cancer, and it will be commissioned in two phases.

In First Phase, we will be filing DMFs with US FDA for Quinapril, Ramipril, Benazepril, Venlafaxine , Bambuterol, and R- Salbutamol. In Second Phase we will file DMFs with US FDA for Lisinopril, Trandolapril, Perindopril, Ziprasidone, and Quetiapine.

From Steroid Group, on priority Budesonide, Fluticasone and Mometasone DMFs would be filed, and from Anti -Cancer Range, Bicalutamide, Gemcitabine, Ifosfamide & Imiquimod DMFs would be filed with US -FDA. For EU Markets, on priority Ramipril and Budesnoide CoS being applied for in Nov. 2004, and other CoS applications for other APIs will be filed over a period of next six months.

Aarti Healthcare has a full-fledged R&D Center with highly qualified and experienced chemists about 40 in No. and expected to be about 100, by turn of the year. Aarti Healthcare is looking for business partners both in Regulated and Non-Regulated Markets, for promotion of its API's, and for mutual benefit and growth."